Clinical characteristics of validation datasets
| Clinical characteristics | Category | SG-3 n (%) | AU-2 n (%) | YGC n (%) | Total n (%) |
|---|---|---|---|---|---|
| Total | 153 (100) | 70 (100) | 65 (100) | 288 (100) | |
| Gender | Male | 95 (62.1) | 48 (68.6) | 46 (70.8) | 189 (65.6) |
| Female | 53 (34.6) | 22 (31.4) | 19 (29.2) | 94 (32.6) | |
| Unknown | 5 (3.3) | 0 (0) | 0 (0) | 5 (1.7) | |
| Age | Median years (min, max) | 65 (23, 92) | 67 (32, 85) | 63 (32, 83) | 65 (23, 92) |
| TNM stage | I | 27 (17.6) | 13 (18.6) | 12 (18.5) | 52 (18.1) |
| II | 25 (16.3) | 16 (22.9) | 2 (3.1) | 43 (14.9) | |
| III | 56 (36.6) | 33 (47.1) | 35 (53.8) | 124 (43.1) | |
| IV | 42 (27.5) | 7 (10) | 16 (24.6) | 65 (22.6) | |
| Unknown | 3 (2) | 1 (1.4) | 0 (0) | 4 (1.4) | |
| Laurén class | Intestinal-type | 72 (47.1) | 34 (48.6) | 20 (30.8) | 126 (43.8) |
| Diffuse-type | 59 (38.6) | 30 (42.9) | 31 (47.7) | 120 (41.7) | |
| Mixed/unclassifiable | 22 (14.4) | 6 (8.6) | 14 (21.5) | 42 (14.6) | |
| Grade of differentiation | Well | 4 (2.6) | 2 (2.9) | ND | 6 (2.1) |
| Moderate | 51 (33.3) | 22 (31.4) | ND | 73 (25.3) | |
| Poor | 91 (59.5) | 26 (37.1) | ND | 117 (40.6) | |
| Undifferentiated/unknown | 7 (4.6) | 20 (28.6) | 65 (100) | 92 (31.9) | |
| Resection margin status | Negative | 110 (71.9) | 66 (94.3) | ND | 176 (61.1) |
| Positive | 17 (11.1) | 4 (5.7) | ND | 21 (7.3) | |
| Unknown | 26 (17) | 0 (0) | 65 (100) | 91 (31.6) | |
| Non-malignant gastric samples | Matched to GC | 38 | 9 | 14 | 61 |
‘ND’ data is not available.
Three independent datasets (Singapore (SG-3), Australia (AU-2) and South Korea (YGC)), comprising 349 samples (288 tumours and 61 non-malignant gastric samples) not included in the initial network construction, were used to validate the coexpression network.